Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC - ADR

NAS:ADAP (UK)   ADR
$ 0.58 -0.0092 (-1.56%) 11:08 PM EST
At Loss
P/B:
1.85
Market Cap:
$ 150.46M
Enterprise V:
$ 43.16M
Volume:
1.20M
Avg Vol (2M):
2.25M
Trade In:
Volume:
1.20M
At Loss
Avg Vol (2M):
2.25M

Business Description

Adaptimmune Therapeutics PLC logo
Adaptimmune Therapeutics PLC
NAICS : 325412 SIC : 2834
ISIN : US00653A1079

Share Class Description:

ADAP: ADR
Description
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Name Current Vs Industry Vs History
Cash-To-Debt 2.5
Equity-to-Asset 0.25
Debt-to-Equity 0.93
Debt-to-EBITDA -1.3
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.32
Distress
Grey
Safe
Beneish M-Score -1.14
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 25.24
9-Day RSI 31.23
14-Day RSI 34.54
6-1 Month Momentum % -24.87
12-1 Month Momentum % 32.32

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.85
Quick Ratio 3.82
Cash Ratio 2.93
Days Sales Outstanding 10.36

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -13.6
Shareholder Yield % -32.01

Financials (Next Earnings Date:2025-03-06 Est.)

ADAP's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ADAP

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Adaptimmune Therapeutics PLC Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 175.041
EPS (TTM) ($) -0.18
Beta 2.27
Volatility % 108.08
14-Day RSI 34.54
14-Day ATR ($) 0.045198
20-Day SMA ($) 0.642185
12-1 Month Momentum % 32.32
52-Week Range ($) 0.5005 - 2.05
Shares Outstanding (Mil) 255.88

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Adaptimmune Therapeutics PLC Filings

Filing Date Document Date Form
No Filing Data

Adaptimmune Therapeutics PLC Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Adaptimmune Therapeutics PLC Frequently Asked Questions

What is Adaptimmune Therapeutics PLC(ADAP)'s stock price today?
The current price of ADAP is $0.58. The 52 week high of ADAP is $2.05 and 52 week low is $0.50.
When is next earnings date of Adaptimmune Therapeutics PLC(ADAP)?
The next earnings date of Adaptimmune Therapeutics PLC(ADAP) is 2025-03-06 Est..
Does Adaptimmune Therapeutics PLC(ADAP) pay dividends? If so, how much?
Adaptimmune Therapeutics PLC(ADAP) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1